In a bold move that underscores its commitment to unlocking value from one of Australia’s most fertile gold provinces, E79 Gold Mines Limited (ASX: E79) has identified several compelling new drill targets at its Laverton South Project. This follows a comprehensive regional review and reinterpretation of large-scale geophysical datasets, inspired partly by the recent Lighthorse discovery by neighbour KalGold (ASX: KAL).

Emyria Limited (ASX: EMD) embodies the fusion of compassionate care, groundbreaking science, and a market in dire need of change. Recently, the company has gained attention by uniquely creating a scalable, evidence-based model for psychedelic-assisted therapy within licensed medical settings in Australia.

In a world where major mineral discoveries are increasingly elusive and hidden beneath cover, Geoscience Australia has crafted a powerful lens into the Earth’s potential—mineral systems-based prospectivity mapping. This approach, backed by decades of data and a deep understanding of geology, is turning Australia into a frontier once again, particularly in the hunt for Iron Oxide Copper-Gold (IOCG) deposits.

Melbourne-based biotech innovator Algorae Pharmaceuticals (ASX: 1AI) is setting the stage for a game-changing therapeutic breakthrough with its combination drug candidate, AI-116, aimed at treating dementia and neurodegenerative disorders.

Heavy Rare Earths Limited (ASX: HRE) has released a March 2025 exploration update that signals major progress across its uranium portfolio. With projects in the uranium-rich Curnamona Province of South Australia and the Mid West region of Western Australia, the company is moving aggressively to define targets through passive seismic, airborne surveys, and historical data analysis.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has unveiled compelling Phase 2 clinical trial data for its lead drug candidate, ATH434—a major advancement in treating Multiple System Atrophy (MSA). The findings were presented at the prestigious European MSA Symposium in London, drawing attention from global experts in neurodegenerative research.

Actinogen Medical Limited (ASX: ACW) is advancing one of the most promising neuroscience drug candidates in the global biotech pipeline. With its novel oral drug Xanamem® (emestedastat), the company is targeting two of the largest and most urgent unmet needs in modern medicine: Alzheimer’s disease (AD) and Major Depressive Disorder (MDD).

Gold never sleeps in the Eastern Goldfields—and neither does Miramar Resources (ASX: M2R). The company has just unveiled another suite of promising gold assay results from its 80%-owned Gidji Joint Venture (JV) Project, located just 15km north of Kalgoorlie. These results continue to reinforce the project's potential to host a major new gold camp and come as the Australian dollar gold price surges past A$5,000/oz.

If there’s one event this year that has the potential to redefine the future of artificial intelligence, it’s SuperAI Singapore 2025. From the viewpoint of someone who’s been observing tech events and innovation cycles for decades, SuperAI is not just another glossy tech conference—it’s a statement.

Peak Minerals Limited (ASX: PUA) has just released a pivotal update that could reshape its future trajectory—and possibly that of the titanium feedstock market. Their latest announcement from the Minta Rutile Project in Cameroon signals the early definition of a rutile province of potentially global significance.